Online first
Clinical vignette
Published online: 2024-06-03
Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!
Abstract
Not required for Clinical Vignette.
Keywords: daratumumabpomalidomideultra-fractionated whole breast irradiation
References
- Murray Brunt A, Haviland JS, Wheatley DA, et al. FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020; 395(10237): 1613–1626.
- Brunt AM, Wheatley D, Yarnold J, et al. FAST-Forward Trial Management Group. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016; 120(1): 114–118.
- Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma. Cancer. 2019; 125(14): 2364–2382.
- Kastritis E, Palladini G, Minnema MC, et al. ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021; 385(1): 46–58.
- Elhassadi E, Murphy M, Hacking D, et al. Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. Clin Case Rep. 2018; 6(4): 723–728.
- Resende Salgado L, Wang S, Adler A, et al. The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era. Adv Radiat Oncol. 2019; 4(1): 112–117.
- Engelhardt M, Wäsch R, Reinhardt H, Kleber M. Pomalidomide. In: Martens UM. ed. Small molecules in oncology. Springer 2014: 359–372.
- Barlas C, Dağdelen M, Elverdi T, et al. Successful Treatment Of Bulky Abdominal Plasmacytomas With Radiotherapy and Pomalidomide. East J Med. 2022; 27(2): 330–332.